PHAT

Phathom Pharmaceuticals Inc

PHAT, USA

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

https://www.phathompharma.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
PHAT
stock
PHAT

Raymond James Financial Begins Coverage on Phathom Pharmaceuticals (NASDAQ:PHAT) MarketBeat

Read more →
PHAT
stock
PHAT

Phathom Pharmaceuticals (NASDAQ:PHAT) Reaches New 12-Month High - What's Next? MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$23.125

Analyst Picks

Strong Buy

6

Buy

2

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-2.53

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

7.09 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-12.47 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-28.57 %

Low ≤ 5%

High ≥ 15%

Investors

* Institutions hold a combined 74.16% of the total shares of Phathom Pharmaceuticals Inc

1.

Medicxi Ventures Management (Jersey) Ltd

(10.5218%)

since

2025/06/30

2.

Amvescap Plc.

(5.8357%)

since

2025/06/30

3.

The Carlyle Group Inc

(4.929%)

since

2025/06/30

4.

BlackRock Inc

(4.6732%)

since

2025/06/30

5.

Vanguard Group Inc

(3.9289%)

since

2025/06/30

6.

Ensign Peak Advisors Inc

(3.5521%)

since

2025/06/30

7.

Millennium Management LLC

(3.1722%)

since

2025/06/30

8.

683 Capital Management LLC

(2.9671%)

since

2025/06/30

9.

Invesco Global A

(2.7844%)

since

2025/07/31

10.

Invesco OFI Global Equity

(2.7844%)

since

2025/06/30

11.

NEA Management Company, LLC

(2.763%)

since

2025/06/30

12.

Vanguard Total Stock Mkt Idx Inv

(2.1906%)

since

2025/07/31

13.

Wasatch Advisors LP

(2.0606%)

since

2025/06/30

14.

Catalys Pacific LLC

(1.6451%)

since

2025/06/30

15.

Geode Capital Management, LLC

(1.5081%)

since

2025/06/30

16.

Avidity Partners Management LP

(1.5005%)

since

2025/06/30

17.

GW&K Investment Management, LLC

(1.4779%)

since

2025/06/30

18.

Wasatch Ultra Growth

(1.4248%)

since

2025/06/30

19.

iShares Russell 2000 ETF

(1.4136%)

since

2025/08/31

20.

Propel Bio Management LLC

(1.3009%)

since

2025/06/30

21.

Strategic Advisers U.S. Total Stock

(1.2743%)

since

2025/07/31

22.

State Street Corp

(1.1973%)

since

2025/06/30

23.

Catalio Capital Management, LP

(0.9476%)

since

2025/06/30

24.

Moore Capital Management, LP

(0.8457%)

since

2025/06/30

25.

Simplify Asset Management Inc.

(0.7357%)

since

2025/06/30

26.

Citigroup Inc

(0.7291%)

since

2025/06/30

27.

Vanguard Institutional Extnd Mkt Idx Tr

(0.6996%)

since

2025/07/31

28.

Fidelity Small Cap Index

(0.5974%)

since

2025/06/30

29.

Invesco VI Global I

(0.5459%)

since

2025/07/31

30.

Simplify Propel Opportunities ETF

(0.4538%)

since

2025/07/31

31.

Columbia Small Cap Value Discv A

(0.4407%)

since

2025/07/31

32.

JNL/Invesco Global Growth A

(0.4275%)

since

2025/06/30

33.

Invesco Dorsey Wright SmallCap Momt ETF

(0.4034%)

since

2025/08/29

34.

Invesco Dorsey Wright Healthcare MomtETF

(0.402%)

since

2025/08/29

35.

iShares Russell 2000 Value ETF

(0.3814%)

since

2025/08/31

36.

Fidelity Extended Market Index

(0.3423%)

since

2025/07/31

37.

Wasatch Micro Cap

(0.3407%)

since

2025/06/30

38.

BrighthouseI Invesco Global Equity A

(0.3402%)

since

2025/06/30

39.

iShares Biotechnology ETF

(0.3157%)

since

2025/08/31

40.

Schwab US Small-Cap ETFâ„¢

(0.3081%)

since

2025/08/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.2876

Latest Release

Date

2025-09-30

EPS Actual

-0.15

EPS Estimate

-0.47

EPS Difference

0.32

Surprise Percent

68.0851%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(1)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(2.5)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(0.5)
Quality
Low Quality Business(0.5)
Value
Overpriced(1)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.